Pediatric anaphylaxis at a university hospital including the rate of prescribing epinephrine auto-injectors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gang, Jun Seak | - |
dc.contributor.author | Kim, Hye-Sun | - |
dc.contributor.author | Bang, Hyun Ho | - |
dc.contributor.author | Kim, Tae Ho | - |
dc.contributor.author | Lee, Hyun Jung | - |
dc.contributor.author | Hwangbo, Young | - |
dc.contributor.author | Park, Joon Soo | - |
dc.date.accessioned | 2021-08-11T14:44:31Z | - |
dc.date.available | 2021-08-11T14:44:31Z | - |
dc.date.issued | 2017-05 | - |
dc.identifier.issn | 2288-0402 | - |
dc.identifier.issn | 2288-0410 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/7575 | - |
dc.description.abstract | Purpose: Anaphylaxis is an acute, life-threatening systemic reaction which should be treated by epinephrine, and patients should be prescribed epinephrine auto-injector after the event. The purpose of this study was to investigate the clinical features of pediatric anaphylaxis, including the rate of using epinephrine at hospital and prescribing epinephrine auto-injector. Methods: We performed a retrospective study of 68 anaphylactic patients at in-hospital, out-hospital, and Emergency Department of Soonchunhyang University Cheonan Hospital, Cheonan, Korea, who were under 15 years of age, from January 2013 through December 2014. We reviewed their clinical features, doctor's treatment methods, rate of follow-up and prescribing epinephrine autoinjectors. Results: Causes of anaphylaxis were food (76.5%), drug (10.3%), and idiopathic (13.2%). The involved organs were the skin (86.8%), respiratory tract (80.9%), cardiovascular system (23.5%), and gastrointestinal tract (17.7%). Patients were treated with systemic steroids (91.2%), antihistamines (88.2%), and epinephrine (75.0%). Fifty-three patients (77.9%) revisited our pediatric allergy clinic and epinephrine auto-injectors were prescribed for 25 patients (36.8%). Conclusion: Physicians should make an effort to use epinephrine as an initial treatment of anaphylaxis, to prescribe epinephrine auto-injectors, and to give proper information about disease. | - |
dc.format.extent | 6 | - |
dc.language | 한국어 | - |
dc.language.iso | KOR | - |
dc.publisher | 대한 소아알레르기 호흡기학회 | - |
dc.title | Pediatric anaphylaxis at a university hospital including the rate of prescribing epinephrine auto-injectors | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.4168/aard.2017.5.3.135 | - |
dc.identifier.wosid | 000424464400004 | - |
dc.identifier.bibliographicCitation | Allergy Asthma & Respiratory Diseases, v.5, no.3, pp 135 - 140 | - |
dc.citation.title | Allergy Asthma & Respiratory Diseases | - |
dc.citation.volume | 5 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 135 | - |
dc.citation.endPage | 140 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002225526 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | esci | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Allergy | - |
dc.relation.journalWebOfScienceCategory | Allergy | - |
dc.subject.keywordPlus | ALLERGIC REACTIONS | - |
dc.subject.keywordPlus | EMERGENCY | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | FOOD | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | DIAGNOSIS | - |
dc.subject.keywordPlus | AMERICA | - |
dc.subject.keywordAuthor | Anaphylaxis | - |
dc.subject.keywordAuthor | Epinephrine | - |
dc.subject.keywordAuthor | Management | - |
dc.subject.keywordAuthor | Child | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.